An algorithm for managing warfarin resistance

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 12, 2009, Pages 724-730

  Osinbowale, Olusegun ^a   Malki, Monzr Al ^b   Schade, Andrew ^c   Bartholomew, John R ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ALGORITHM; DOSE RESPONSE; DRUG MONITORING; DRUG RESISTANCE; HUMAN; METHODOLOGY; REVIEW;

ALGORITHMS; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE; HUMANS; WARFARIN;

EID: 74249109543     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.09062     Document Type: Review

References (37)

1. Lefrere JJ, Horellou MH, Conard J, Samama M. Proposed classification of resistance to oral anticoagulant therapy. J Clin Pathol 1987; 40:242.
2. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. Clin Chim Acta 2001; 308:9-15.
3. Thijssen HH. Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance gene is not irreversibly blocked by warfarin. Biochem Pharmacol 1987; 36:2753-2757.
4. Hulse ML. Warfarin resistance: diagnosis and therapeutic alternative. Pharmacotherapy 1996; 16:1009-1017.
5. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108(suppl 4):231S-234S.
6. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13:247-252.
7. Daly AK, Aithal GP. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 2003; 3:231-238.
8. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40:587-603.
9. Retti AE, Wienkers LC, Gonzalez FJ, Trager WF, Korezekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allele variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
10. Porter RS, Sawyer WR. Warfarin. In: Evans WE, Shentag JJ, Jusko WJ, editors. Applied Pharmacokinetics. Principles of Therapeutics Drug Monitoring, 3rd ed. Washington, DC: Applied Therapeutics, 1992:31.1-31.46.
11. Warrell DA, Cox TM, Firth JD. Oxford Textbook of Medicine, 4th ed. Oxford University Press, 2003:734.
12. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095-1106.
13. Medical Economics Staff. Physicians' Desk Reference, 55th Ed. Medical Economics, 2001:1139-1140.
14. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999-1008.
15. Diab F, Feffer S. Hereditary warfarin resistance. South Med J 1994; 87:407-409.
16. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med 1970; 282:1448-1451.
17. O'Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin ML. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Engl J Med 1964; 271:809-815.
18. Alving BM, Strickler MP, Knight RD, Barr CF, Berenberg JL, Peek CC. Hereditary warfarin resistance. Investigation of rare phenomenon. Arch Intern Med 1985; 145:499-501.
19. Warrier L, Brennan CA, Lusher JM. Familial warfarin resistance in a black child. Am J Pediatr Hematol Oncol 1986; 8:346-347.
20. Nikkila EA, Pelkonen R. Serum lipid-reducing agents and anticoagulant requirement. Lancet 1963; 1:332.
21. Robinson A, Liau FO, Routledge PA, Backhouse G, Spragg BP, Bentley DP. Lipids and warfarin requirements. Thromb Haemost 1990; 63:148-149.
22. MacLaren R, Wachsman BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy 1997; 17:1331-1337.
23. DeCurtis A, D'Adamo MC, Amore C, et al. Experimental arterial thrombosis in genetically or diet induced hyperlipidemia in rats-role of vitamin K-dependent clotting factors and prevention by low-intensity oral anticoagulation. Thromb Haemost 2001; 86:1440-1448.
24. O'Reilly RA. Drug interaction involving oral anticoagulation. In: Melmon KL, editor. Cardiovascular Drug Therapy, Philadelphia; FA Davis, 1975:23-41.
25. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulation drugs in man and rat. Ann N Y Acad Sci 1968; 151:913-931.
26. Cain D, Hutson SM, Wallin R. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. Thromb Haemost 1998; 80:128-133.
27. Rodvold KA, Quandt CM, Friedenberg WR. Thromboembolic disorders. In: DiPiro JT, Talbert RL, editors. Pharmacotherapy. A Pathophysiologic Approach, 2nd ed. New York: Elsevier, 1992:312-335.
28. Park BK. Warfarin: metabolism and mode of action. Biochem Pharmacol 1988; 37:19-27.
29. Cain D, Hutson SM, Wallin R. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 1997; 272:29068-29075.
30. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium binding proteins and vitamin K. N Engl J Med 1980; 302:1460-1466.
31. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:537-541.
32. Loebstein R, Dovskin I, Halkin H, et al. A coding VKORC1 Asp36-Tyr polymorphism predisposes to warfarin resistance. Blood 2007;109:2477-2480.
33. Bentley DP, Backhouse G, Hutchings A, Haddon RL, Spragg B, Routledge PA. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986; 22:37-41.
34. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-2775.
35. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31-39.
36. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786.
37. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101:77-85.